Ubs Group Ag Black Diamond Therapeutics, Inc. Transaction History
Ubs Group Ag
- $528 Billion
- Q1 2025
A detailed history of Ubs Group Ag transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 127,794 shares of BDTX stock, worth $329,708. This represents 0.0% of its overall portfolio holdings.
Number of Shares
127,794
Previous 49,893
156.14%
Holding current value
$329,708
Previous $106,000
86.79%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$26.8 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$14.4 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$11.5 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$7.05 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $93.8M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...